Through R&D innovations and collaborative partnerships, we're investing in cutting-edge research to open
the door for new assay development that Power the Moments That Matter
Improving Access to Blood-based Biomarker Assays
We are partnering with leading clinical researchers to create a discovery ecosystem to unlock the full potential of the latest scientific advances—developing a robust portfolio of highly sensitive RUO assays that can ultimately be used to advance neurodegenerative disease diagnostics to enable earlier disease detection.
Our goal? To change the paradigm of patient care with less invasive assays that deliver more insights into neurodegenerative diseases.
Leveraging our IVD expertise, we’re innovating best-in-class, highly sensitive blood-based biomarker assays to improve disease research.
We’re pushing boundaries with next-generation technologies that improve workflow with the goal of driving confidence in patient results.
| Assays for Research Use Only | IFU | Information Bulletin |
| p-Tau217 | Link | Link |
| GFAP | Link | Link |
| NfL | Link | Link |
| APOE ε4 | Link | Link |
| ß-AmyIoid 1-42 | Link | Coming Soon |
| BD-Tau | Link | Coming Soon |
| Research Use Only Assays in Development | ||
| MTBR-Tau (CSF) | ||
| TDP-43 | ||
| Assay has been granted BDD from the U.S. FDA | ||
| p-Tau217/ß-AmyIoid 1-42 Plasma Ratio* | ||
*IVD Assay in Development. Not currently for use in diagnostic procedures.
Our newly available APOE ε4 RUO blood-based immunoassay offers >99% concordance with PCR genotyping—in only 20 minutes. While not
diagnostic, APOE ε4 status can provide insights into risk of developing Alzheimer’s disease.
A Multi-Marker pTau-217-Inclusive Approach
Date: Thursday, December 4, 2025
Time: 8:30 AM
Date: Wednesday, December 3
Time: 7:15 AM – 5:30 PM
Poster P194: Automated Plasma Immunoassay for APOE ε4 Zygosity Identification in Alzheimer Disease Risk Assessment
Poster P237: Novel high-throughput, fully automated immunoassay for cerebrospinal fluid tau microtubule binding region (MTBR-Tau)
Poster P223: Multiple Plasma Biomarker Diagnostic Cascade: Performance of the Beckman Coulter p-Tau217, Aβ42, and NfL assays in a cohort of individuals with cognitive impairment
Blood-Based Biomarker Solutions for Alzheimer's Disease Diagnostics
Date: Thursday, December 4, 2025
Time: 3:50 – 4:20 PM
The panel will explore the full arc of diagnostic biomarker development in conjunction with drug development in neurodegenerative diseases (NDDs)—from early discovery to clinical adoption—emphasizing both the scientific opportunities and systemic challenges unique to this therapeutic area. Through case studies, insights from current experiences with biomarker development in NDD, and strategic foresight, we’ll unpack how to responsibly accelerate innovation while building a sustainable path to impact.
Date: Tuesday, December 2, 2025
Time: 7:30 - 8:30 AM
Location: Aqua D
Hilton San Diego Bay Front
1 Park Boulevard, San Diego, CA 92101
Panelists:
Moderator:
A light breakfast will be served.*
*MA/VT physicians: this meal is provided by Beckman Coulter Diagnostics and Danaher in connection to an educational presentation about neurodegenerative disease biomarkers. The approximate value of the meal is $10 per person. By accepting this meal, you acknowledge this disclosure and that Beckman Coulter Diagnostics and Danaher may be required to report this transfer of value to state and federal transparency programs. If you would like to opt out, please notify a team member.
Learn more. Check out these articles:
Tell us you're coming, and we'll connect you with a member of the Beckman Coulter team.
Complete the form below and someone will reach out to you soon.
Thank you for your request.
A Beckman Coulter representative will contact you shortly.
2025-14923
English
